KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares Outstanding
Ratios

Biogen (BIIB) R&D In Process (2017 - 2021)

Biogen has reported R&D In Process over the past 5 years, most recently at $18.0 million for Q2 2021.

  • For Q2 2021, R&D In Process changed N/A year-over-year to $18.0 million; the TTM value through Jun 2022 reached $18.0 million, changed 0.0%, while the annual FY2021 figure was $18.0 million, 76.0% down from the prior year.
  • R&D In Process for Q2 2021 was $18.0 million at Biogen, down from $75.0 million in the prior quarter.
  • Over five years, R&D In Process peaked at $120.0 million in Q2 2017 and troughed at $10.0 million in Q1 2018.
  • A 4-year average of $57.2 million and a median of $75.0 million in 2018 define the central range for R&D In Process.
  • On a YoY basis, R&D In Process climbed as much as 37.5% in 2018 and fell as far as 37.5% in 2018.
  • Year by year, R&D In Process stood at $120.0 million in 2017, then tumbled by 37.5% to $75.0 million in 2018, then changed by 0.0% to $75.0 million in 2020, then crashed by 76.0% to $18.0 million in 2021.
  • Business Quant data shows R&D In Process for BIIB at $18.0 million in Q2 2021, $75.0 million in Q1 2020, and $75.0 million in Q4 2018.